# An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

> **NCT01848340** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 16 (actual)

## Conditions studied

- HIV-associated Lipodystrophy Syndrome

## Interventions

- **DRUG:** GSK1265744B (sodium salt) containing 14C-GSK1265744B
- **DRUG:** 150 mg GSK1265744B
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01848340
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2013-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01848340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01848340, "An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01848340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*